You searched for "tumours"
Evaluating the ‘two-week wait pathway’ for testicular cancer
The ‘Two-Week Wait’ (2WW) pathway is central to the NHS cancer strategy, ensuring rapid review of suspected malignancies. For testicular cancer, NICE NG12 advises urgent referral based solely on clinical suspicion (typically a solid, non-transilluminable scrotal mass) without requiring prior...Focal therapies in prostate cancer
The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...Redundant! Do urological surgeons have a future in treating urological cancers? RSM Urology Section Meeting
December 2023 marked the latest RSM Urology Section event. Alongside the Winter Short Papers Prize presentations, the theme of the day was major urological cancers and the role of the urologist in patient management within the multidisciplinary team (MDT). We...Penile cancer
Case 1 A 67-year-old man presents with a worsening red patch over the past three months. It looks velvety in some areas. What is the most likely diagnosis? What are the risk factors? How do you classify this condition? How...
Intravesical cytosine arabinoside + Mitomycin C for bladder cancer – is it beneficial?
Mitomycin C (MMC) is often used as an intravesical therapy for low / intermediate risk non-muscle invasive bladder cancer. This randomised controlled trial (RCT) was designed to assess the safety and efficacy of MMC + cytosine arabinoside (Ara-C). Ara-C was...
Intravesical instillation of chemotherapy before radical surgery for upper UTUC
Upper urinary tract urothelial carcinoma (UTUC) is a rare but increasingly prevalent form of urothelial cancer, accounting for 5–10% of cases, with an annual incidence of two to three cases per 100,000 individuals in Western Europe. Radical nephroureterectomy (RNU) with...
The future of bladder preservation for muscle-invasive bladder cancer
Localised muscle-invasive bladder cancer (MIBC) has historically been treated with radical cystectomy (RC), but bladder preservation therapy (BPT) has emerged as a credible and increasingly refined alternative. Early work by Herr in the 1980s demonstrated that radical transurethral resection of...Black men are more at risk from prostate cancer, but we won’t let it stay that way – an update from Prostate Cancer Research
- CHARITY FOCUS - Focusing on all of disease characteristics, societal factors, and better communication gives us real potential to fix a disparity that has persisted for too long. When it comes to health inequity, the numbers are stark. Black...An algorithm for the management of haemorrhagic cystitis
Haemorrhagic cystitis (HC) can be one of the most difficult conditions to treat in urological practice. It is characterised by intractable bleeding from the bladder and may be acute or chronic. The most frequently reported causal factors are radiotherapy (RT)...Stereotactic body radiotherapy for oligometastatic disease secondary to urological cancer
The concept of oligometastatic disease is controversial. The traditional model of cancer, which most of us learnt at medical school, is of a disease which starts confined to an organ, for example the prostate, where it can be cured with...
Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy
Neutrophil-to-lymphocyte ratio has been shown to be a prognostic factor in a number of different cancers. This is one of the largest studies to date to evaluate its effect on overall survival in patients who have undergone radical prostatectomy (RP)...
